A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint

被引:0
|
作者
Qing, Yun [1 ,2 ]
Thall, Peter F. [1 ]
Yuan, Ying [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[2] Univ Texas Hlth Sci Ctr Houston, Dept Biostat & Data Sci, Houston, TX 77030 USA
关键词
Bayesian adaptive design; futility monitoring; go; no-go decision; interim analysis; OPTIMAL 2-STAGE DESIGNS; CLINICAL-TRIALS; SURVIVAL; SAMPLE;
D O I
10.1002/pst.2256
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A robust Bayesian design is presented for a single-arm phase II trial with an early stopping rule to monitor a time to event endpoint. The assumed model is a piecewise exponential distribution with non-informative gamma priors on the hazard parameters in subintervals of a fixed follow up interval. As an additional comparator, we also define and evaluate a version of the design based on an assumed Weibull distribution. Except for the assumed models, the piecewise exponential and Weibull model based designs are identical to an established design that assumes an exponential event time distribution with an inverse gamma prior on the mean event time. The three designs are compared by simulation under several log-logistic and Weibull distributions having different shape parameters, and for different monitoring schedules. The simulations show that, compared to the exponential inverse gamma model based design, the piecewise exponential design has substantially better performance, with much higher probabilities of correctly stopping the trial early, and shorter and less variable trial duration, when the assumed median event time is unacceptably low. Compared to the Weibull model based design, the piecewise exponential design does a much better job of maintaining small incorrect stopping probabilities in cases where the true median survival time is desirably large.
引用
收藏
页码:34 / 44
页数:11
相关论文
共 50 条
  • [41] Sample size calculation for cluster randomization trials with a time-to-event endpoint
    Li, Jianghao
    Jung, Sin-Ho
    STATISTICS IN MEDICINE, 2020, 39 (25) : 3608 - 3623
  • [42] Bayesian time-to-event analysis of high blood pressure
    Shriner, Daniel
    Bentleys, Amy R.
    Adeyemo, Adebowale
    Rotimi, Charles N.
    GENETIC EPIDEMIOLOGY, 2018, 42 (07) : 731 - 731
  • [43] A Bayesian approach for event predictions in clinical trials with time-to-event outcomes
    Aubel, Paul
    Antigny, Marine
    Fougeray, Ronan
    Dubois, Frederic
    Saint-Hilary, Gaelle
    STATISTICS IN MEDICINE, 2021, 40 (28) : 6344 - 6359
  • [44] A randomized phase II design with a time-to-event endpoint using predictive probability of success of the follow-up phase III study as the criteria for go/no-go decision.
    Chen, B.
    Fan, X.
    Wang, Y.
    Jauffret, S.
    Dey, J.
    Waltzman, R.
    Lopez-Martin, E. M.
    Malek, K.
    Kreitz, S.
    Zuber, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] Bayesian methods for setting sample sizes and choosing allocation ratios in phase II clinical trials with time-to-event endpoints
    Cotterill, Amy
    Whitehead, John
    STATISTICS IN MEDICINE, 2015, 34 (11) : 1889 - 1903
  • [46] Exploring the benefits of adaptive sequential designs in time-to-event endpoint settings
    Emerson, Sarah C.
    Rudser, Kyle D.
    Emerson, Scott S.
    STATISTICS IN MEDICINE, 2011, 30 (11) : 1199 - 1217
  • [47] BEATS: Bayesian hybrid design with flexible sample size adaptation for time-to-event endpoints
    Bi, Dehua
    Liu, Meizi
    Lin, Jianchang
    Liu, Rachael
    STATISTICS IN MEDICINE, 2023, 42 (30) : 5708 - 5722
  • [48] Bayesian design of clinical trials using joint models for longitudinal and time-to-event data
    Xu, Jiawei
    Psioda, Matthew A.
    Ibrahim, Joseph G.
    BIOSTATISTICS, 2022, 23 (02) : 591 - 608
  • [49] A Bayesian model for time-to-event data with informative censoring
    Kaciroti, Niko A.
    Raghunathan, Trivellore E.
    Taylor, Jeremy M. G.
    Julius, Stevo
    BIOSTATISTICS, 2012, 13 (02) : 341 - 354
  • [50] Bayesian design of clinical trials with multiple time-to-event outcomes subject to functional cure
    Cho, Seoyoon
    Psioda, Matthew A.
    Ibrahim, Joseph G.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2025,